APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Hypertension Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Hypertension Drug Market Outlook and Growth Opportunities 2026

Report ID 174029990426 December 2025194 pages

Choose your research edition.

Industry ResearchPulmonary Hypertension Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Hypertension Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Pulmonary Hypertension Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Hypertension Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Hypertension Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Pulmonary Hypertension Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Hypertension Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Hypertension Drug market include Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd., Ikaria Inc., Proreo Pharma AG, Vectura Group plc, Vicore Pharma AB, Bayer AG and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Hypertension Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Hypertension Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Hypertension Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Hypertension Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Hypertension Drug Segment by Company

Biolab Sanus Farmaceutica Ltda.

Hanmi Pharmaceuticals, Co. Ltd.

Ikaria Inc.

Proreo Pharma AG

Vectura Group plc

Vicore Pharma AB

Bayer AG

Sanofi

Pulmonary Hypertension Drug Segment by Type

IK-3001

Riociguat

Sildenafil Citrate IMD

SAR-407899

IK-7002

Others

Pulmonary Hypertension Drug Segment by Application

Clinic

Hospital

Others

Pulmonary Hypertension Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pulmonary Hypertension Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pulmonary Hypertension Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Hypertension Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Hypertension Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Hypertension Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Hypertension Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Hypertension Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Hypertension Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Hypertension Drug industry.

Chapter 3: Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pulmonary Hypertension Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pulmonary Hypertension Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Hypertension Drug Industry Trends Table 2. Pulmonary Hypertension Drug Industry Drivers Table 3. Pulmonary Hypertension Drug Industry Opportunities and Challenges Table 4. Pulmonary Hypertension Drug Industry Restraints Table 5. Global Pulmonary Hypertension Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Hypertension Drug Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Hypertension Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Pulmonary Hypertension Drug Sales Volume Share by Company (2021-2026) Table 9. Global Pulmonary Hypertension Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pulmonary Hypertension Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pulmonary Hypertension Drug Key Company Manufacturing Base & Headquarters Table 12. Global Pulmonary Hypertension Drug Company, Product Type & Application Table 13. Global Pulmonary Hypertension Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of IK-3001 Table 18. Significant Companies of Riociguat Table 19. Significant Companies of Sildenafil Citrate IMD Table 20. Significant Companies of SAR-407899 Table 21. Significant Companies of IK-7002 Table 22. Significant Companies of Others Table 23. Global Pulmonary Hypertension Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Pulmonary Hypertension Drug Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Pulmonary Hypertension Drug Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Pulmonary Hypertension Drug Sales Volume Share by Type (2021-2026) Table 27. Global Pulmonary Hypertension Drug Sales Volume Share by Type (2027-2032) Table 28. Global Pulmonary Hypertension Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pulmonary Hypertension Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Pulmonary Hypertension Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Pulmonary Hypertension Drug Sales Value Share by Type (2021-2026) Table 32. Global Pulmonary Hypertension Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Hospital Table 35. Significant Companies of Others Table 36. Global Pulmonary Hypertension Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Pulmonary Hypertension Drug Sales Volume by Application (2021-2026) & (W Units) Table 38. Global Pulmonary Hypertension Drug Sales Volume by Application (2027-2032) & (W Units) Table 39. Global Pulmonary Hypertension Drug Sales Volume Share by Application (2021-2026) Table 40. Global Pulmonary Hypertension Drug Sales Volume Share by Application (2027-2032) Table 41. Global Pulmonary Hypertension Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Pulmonary Hypertension Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Pulmonary Hypertension Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Pulmonary Hypertension Drug Sales Value Share by Application (2021-2026) Table 45. Global Pulmonary Hypertension Drug Sales Value Share by Application (2027-2032) Table 46. Global Pulmonary Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Pulmonary Hypertension Drug Sales by Region (2021-2026) & (W Units) Table 48. Global Pulmonary Hypertension Drug Sales Market Share by Region (2021-2026) Table 49. Global Pulmonary Hypertension Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Pulmonary Hypertension Drug Sales Market Share by Region (2027-2032) Table 51. Global Pulmonary Hypertension Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Pulmonary Hypertension Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Pulmonary Hypertension Drug Sales Value Share by Region (2021-2026) Table 54. Global Pulmonary Hypertension Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Pulmonary Hypertension Drug Sales Value Share by Region (2027-2032) Table 56. Global Pulmonary Hypertension Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Pulmonary Hypertension Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Pulmonary Hypertension Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Global Pulmonary Hypertension Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Pulmonary Hypertension Drug Sales by Country (2021-2026) & (W Units) Table 61. Global Pulmonary Hypertension Drug Sales Market Share by Country (2021-2026) Table 62. Global Pulmonary Hypertension Drug Sales by Country (2027-2032) & (W Units) Table 63. Global Pulmonary Hypertension Drug Sales Market Share by Country (2027-2032) Table 64. Global Pulmonary Hypertension Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Pulmonary Hypertension Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Pulmonary Hypertension Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Pulmonary Hypertension Drug Sales Value Market Share by Country (2027-2032) Table 68. Biolab Sanus Farmaceutica Ltda. Company Information Table 69. Biolab Sanus Farmaceutica Ltda. Business Overview Table 70. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio Table 72. Biolab Sanus Farmaceutica Ltda. Recent Development Table 73. Hanmi Pharmaceuticals, Co. Ltd. Company Information Table 74. Hanmi Pharmaceuticals, Co. Ltd. Business Overview Table 75. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio Table 77. Hanmi Pharmaceuticals, Co. Ltd. Recent Development Table 78. Ikaria Inc. Company Information Table 79. Ikaria Inc. Business Overview Table 80. Ikaria Inc. Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio Table 82. Ikaria Inc. Recent Development Table 83. Proreo Pharma AG Company Information Table 84. Proreo Pharma AG Business Overview Table 85. Proreo Pharma AG Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio Table 87. Proreo Pharma AG Recent Development Table 88. Vectura Group plc Company Information Table 89. Vectura Group plc Business Overview Table 90. Vectura Group plc Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Vectura Group plc Pulmonary Hypertension Drug Product Portfolio Table 92. Vectura Group plc Recent Development Table 93. Vicore Pharma AB Company Information Table 94. Vicore Pharma AB Business Overview Table 95. Vicore Pharma AB Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio Table 97. Vicore Pharma AB Recent Development Table 98. Bayer AG Company Information Table 99. Bayer AG Business Overview Table 100. Bayer AG Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Bayer AG Pulmonary Hypertension Drug Product Portfolio Table 102. Bayer AG Recent Development Table 103. Sanofi Company Information Table 104. Sanofi Business Overview Table 105. Sanofi Pulmonary Hypertension Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Sanofi Pulmonary Hypertension Drug Product Portfolio Table 107. Sanofi Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Pulmonary Hypertension Drug Distributors List Table 111. Pulmonary Hypertension Drug Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Pulmonary Hypertension Drug Product Image Figure 2. Global Pulmonary Hypertension Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Hypertension Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Hypertension Drug Sales (2021-2032) & (W Units) Figure 5. Global Pulmonary Hypertension Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pulmonary Hypertension Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. IK-3001 Image Figure 10. Riociguat Image Figure 11. Sildenafil Citrate IMD Image Figure 12. SAR-407899 Image Figure 13. IK-7002 Image Figure 14. Others Image Figure 15. Global Pulmonary Hypertension Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Pulmonary Hypertension Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Pulmonary Hypertension Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Pulmonary Hypertension Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pulmonary Hypertension Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Pulmonary Hypertension Drug Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Pulmonary Hypertension Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Pulmonary Hypertension Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Pulmonary Hypertension Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Pulmonary Hypertension Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Pulmonary Hypertension Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Pulmonary Hypertension Drug Sales Value Share by Application (2021-2032) Figure 30. Global Pulmonary Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 31. Global Pulmonary Hypertension Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Pulmonary Hypertension Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Pulmonary Hypertension Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Pulmonary Hypertension Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Pulmonary Hypertension Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Pulmonary Hypertension Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Pulmonary Hypertension Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Pulmonary Hypertension Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Pulmonary Hypertension Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Pulmonary Hypertension Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Pulmonary Hypertension Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Pulmonary Hypertension Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Pulmonary Hypertension Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Pulmonary Hypertension Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Pulmonary Hypertension Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • IK-3001
  • Riociguat
  • Sildenafil Citrate IMD
  • SAR-407899
  • IK-7002
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Biolab Sanus Farmaceutica Ltda.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Ikaria Inc.
  • Proreo Pharma AG
  • Vectura Group plc
  • Vicore Pharma AB
  • Bayer AG
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Hypertension Drug Sales Value (2021-2032)
  4. 1.2.2 Global Pulmonary Hypertension Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Pulmonary Hypertension Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pulmonary Hypertension Drug Market Dynamics
  1. 2.1 Pulmonary Hypertension Drug Industry Trends
  2. 2.2 Pulmonary Hypertension Drug Industry Drivers
  3. 2.3 Pulmonary Hypertension Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Hypertension Drug Industry Restraints
3 Pulmonary Hypertension Drug Market by Company
  1. 3.1 Global Pulmonary Hypertension Drug Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Hypertension Drug Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Hypertension Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Pulmonary Hypertension Drug Average Price by Company (2021-2026)
  5. 3.5 Global Pulmonary Hypertension Drug Company Ranking (2024-2026)
  6. 3.6 Global Pulmonary Hypertension Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Pulmonary Hypertension Drug Company Product Type and Application
  8. 3.8 Global Pulmonary Hypertension Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pulmonary Hypertension Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pulmonary Hypertension Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pulmonary Hypertension Drug Market by Type
  1. 4.1 Pulmonary Hypertension Drug Type Introduction
  2. 4.1.1 IK-3001
  3. 4.1.2 Riociguat
  4. 4.1.3 Sildenafil Citrate IMD
  5. 4.1.4 SAR-407899
  6. 4.1.5 IK-7002
  7. 4.1.6 Others
  8. 4.2 Global Pulmonary Hypertension Drug Sales Volume by Type
  9. 4.2.1 Global Pulmonary Hypertension Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Pulmonary Hypertension Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Pulmonary Hypertension Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Pulmonary Hypertension Drug Sales Value by Type
  13. 4.3.1 Global Pulmonary Hypertension Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Pulmonary Hypertension Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Pulmonary Hypertension Drug Sales Value Share by Type (2021-2032)
5 Pulmonary Hypertension Drug Market by Application
  1. 5.1 Pulmonary Hypertension Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Pulmonary Hypertension Drug Sales Volume by Application
  6. 5.2.1 Global Pulmonary Hypertension Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pulmonary Hypertension Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pulmonary Hypertension Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pulmonary Hypertension Drug Sales Value by Application
  10. 5.3.1 Global Pulmonary Hypertension Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pulmonary Hypertension Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pulmonary Hypertension Drug Sales Value Share by Application (2021-2032)
6 Pulmonary Hypertension Drug Regional Sales and Value Analysis
  1. 6.1 Global Pulmonary Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Hypertension Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Hypertension Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Hypertension Drug Sales by Region (2027-2032)
  5. 6.3 Global Pulmonary Hypertension Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pulmonary Hypertension Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pulmonary Hypertension Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pulmonary Hypertension Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Pulmonary Hypertension Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pulmonary Hypertension Drug Sales Value (2021-2032)
  12. 6.6.2 North America Pulmonary Hypertension Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pulmonary Hypertension Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Pulmonary Hypertension Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pulmonary Hypertension Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pulmonary Hypertension Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pulmonary Hypertension Drug Sales Value (2021-2032)
  21. 6.9.2 South America Pulmonary Hypertension Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pulmonary Hypertension Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pulmonary Hypertension Drug Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Hypertension Drug Country-level Sales and Value Analysis
  1. 7.1 Global Pulmonary Hypertension Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Hypertension Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pulmonary Hypertension Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Pulmonary Hypertension Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Pulmonary Hypertension Drug Sales by Country (2027-2032)
  6. 7.4 Global Pulmonary Hypertension Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pulmonary Hypertension Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pulmonary Hypertension Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pulmonary Hypertension Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pulmonary Hypertension Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pulmonary Hypertension Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biolab Sanus Farmaceutica Ltda.
  2. 8.1.1 Biolab Sanus Farmaceutica Ltda. Company Information
  3. 8.1.2 Biolab Sanus Farmaceutica Ltda. Business Overview
  4. 8.1.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
  6. 8.1.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
  7. 8.2 Hanmi Pharmaceuticals, Co. Ltd.
  8. 8.2.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
  9. 8.2.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
  10. 8.2.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
  12. 8.2.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
  13. 8.3 Ikaria Inc.
  14. 8.3.1 Ikaria Inc. Company Information
  15. 8.3.2 Ikaria Inc. Business Overview
  16. 8.3.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio
  18. 8.3.5 Ikaria Inc. Recent Developments
  19. 8.4 Proreo Pharma AG
  20. 8.4.1 Proreo Pharma AG Company Information
  21. 8.4.2 Proreo Pharma AG Business Overview
  22. 8.4.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
  24. 8.4.5 Proreo Pharma AG Recent Developments
  25. 8.5 Vectura Group plc
  26. 8.5.1 Vectura Group plc Company Information
  27. 8.5.2 Vectura Group plc Business Overview
  28. 8.5.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
  30. 8.5.5 Vectura Group plc Recent Developments
  31. 8.6 Vicore Pharma AB
  32. 8.6.1 Vicore Pharma AB Company Information
  33. 8.6.2 Vicore Pharma AB Business Overview
  34. 8.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
  36. 8.6.5 Vicore Pharma AB Recent Developments
  37. 8.7 Bayer AG
  38. 8.7.1 Bayer AG Company Information
  39. 8.7.2 Bayer AG Business Overview
  40. 8.7.3 Bayer AG Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bayer AG Pulmonary Hypertension Drug Product Portfolio
  42. 8.7.5 Bayer AG Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Pulmonary Hypertension Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Pulmonary Hypertension Drug Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Hypertension Drug Value Chain Analysis
  2. 9.1.1 Pulmonary Hypertension Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Hypertension Drug Sales Mode & Process
  6. 9.2 Pulmonary Hypertension Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Hypertension Drug Distributors
  9. 9.2.3 Pulmonary Hypertension Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst